 MSN Pharmaceuticals Inc.	MSN PHARMACEUTICAL INC 20 DUKE ROAD, PISCATAWAY, NJ-08854, USA		Page 1 of 6
	SAFETY DATA SHEET (SDS)		
Product Name	Glycopyrrolate Oral Solution, 1 mg/5 mL	Effective Date: April 2025	

1. Identification

Product Name: Glycopyrrolate Oral Solution, 1 mg/5 mL

Manufacturer: MSN Pharmaceuticals Inc., Piscataway, NJ 08854

2. Hazards Identification

Hazard Statement: This is a pharmaceutical product designed to be prescribed by a licensed health care professional. Should any person while using this product observe any adverse health effects, they should seek medical treatment.

OSHA defined Hazards: This product is not considered to be hazardous per the Occupational Safety & Health Administration's (OSHA's) Hazard Communication Standard 29CFR1910.1200

3. Composition/information on ingredients

Glycopyrrolate, USP: 1 mg/5 mL (0.2 mg/mL)

4. First Aid Measures

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.


Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: Treat Symptomatically

 MSN Pharmaceuticals Inc.	MSN PHARMACEUTICAL INC 20 DUKE ROAD, PISCATAWAY, NJ-08854, USA		Page 2 of 6
	SAFETY DATA SHEET (SDS)		
Product Name	Glycopyrrolate Oral Solution, 1 mg/5 mL	Effective Date: April 2025	

5. Fire Fighting Measures

Extinguishing Media:

Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire
Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions

Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. Accidental Release Measures

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.


Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning /Collecting: Contain the source of the spill or leak. Absorb spills with non-combustible absorbent material and transfer into a labeled container for disposal. Clean spill area thoroughly. Prevent discharge.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

 MSN Pharmaceuticals Inc.	MSN PHARMACEUTICAL INC 20 DUKE ROAD, PISCATAWAY, NJ-08854, USA		Page 3 of 6
	SAFETY DATA SHEET (SDS)		
Product Name	Glycopyrrolate Oral Solution, 1 mg/5 mL	Effective Date: April 2025	

7. Handling and Storage

Precautions for Safe Handling

Restrict access to work area. Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Refer to Section 12 - Ecological Information, for information on potential effects on the environment. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. It is recommended that all operations be fully enclosed and no air recirculated.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. Exposure Controls/Personal Protection

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.


Personal protective Equipment Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

 MSN Pharmaceuticals Inc.	MSN PHARMACEUTICAL INC 20 DUKE ROAD, PISCATAWAY, NJ-08854, USA		Page 4 of 6
	SAFETY DATA SHEET (SDS)		
Product Name	Glycopyrrolate Oral Solution, 1 mg/5 mL	Effective Date: April 2025	

9. Physical and Chemical Properties

Physical State: Liquid
Flavor: Cherry Flavor

10. Stability and Reactivity

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.
Possibility of Hazardous Reactions	
Oxidizing Properties:	No data available
Conditions to Avoid:	None known
Incompatible Materials:	Strong acids, strong oxidizing agents
Hazardous Decomposition Products:	No data available


11. Toxicological Information

Information on Toxicological Effects

General Information:	Handling of formulated drug product is not expected to cause any toxicological effects.
Toxicity data:	Glycopyrrolate Oral LD50 (rat)=709 mg/kg Intraperitoneal LD50 (rat)=196 mg/kg Oral LD50 (mouse)=570 mg/kg
Carcinogenicity:	Long-term animal studies have not been performed to evaluate the carcinogenic potential of glycopyrrolate
Reproductive Effects:	Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. It is not known whether glycopyrrolate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

12. Ecological Information

Environmental Overview: The product is not classified as environmentally hazardous.

 MSN Pharmaceuticals Inc.	MSN PHARMACEUTICAL INC 20 DUKE ROAD, PISCATAWAY, NJ-08854, USA		Page 5 of 6
	SAFETY DATA SHEET (SDS)		
Product Name	Glycopyrrolate Oral Solution, 1 mg/5 mL	Effective Date: April 2025	

13. Disposal Considerations

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. Transport Information

International Regulations: Not Classified by transport regulations, non-regulated

IATA / ICAO – Non-Hazardous - Not Regulated


IATA Proper shipping name: N/A
IATA UN / ID No: N/A
IATA Hazard Class: N/A
IATA Packing Group: N/A
IATA Label: N/A

IMDG – Non-Hazardous - Not Regulated

IMDG Proper shipping name: N/A
IMDG UN / ID No: N/A
IMDG Hazard Class: N/A
IMDG Flash Point N/A
IMDG Label: N/A

DOT – Non-Hazardous - Not Regulated

DOT Proper shipping name: N/A
DOT UN / ID No: N/A
DOT Hazard Class: N/A
DOT Flash Point N/A
DOT Packing Group: N/A
DOT Label: N/A

 MSN Pharmaceuticals Inc.	MSN PHARMACEUTICAL INC 20 DUKE ROAD, PISCATAWAY, NJ-08854, USA		Page 6 of 6
	SAFETY DATA SHEET (SDS)		
Product Name	Glycopyrrolate Oral Solution, 1 mg/5 mL	Effective Date: April 2025	

15. Regulatory Information

Reporting Requirements -

TSCA: All components are listed on the TSCA Inventory or exempt.

SARA 311/312: Not Applicable

SARA 313: This product does not contain any chemicals above reporting thresholds.

16. Other Information

Prepared by: MSN Pharmaceutical Inc, Piscataway, New Jersey – 08554

MSN Pharmaceutical Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

Disclaimer: This SDS is intended to provide a brief summary of our knowledge and guidance regarding the use of this material. It is not meant to be an all-inclusive document on worldwide hazard communications regulations. This information is offered in good faith. Each user of this material needs to evaluate the conditions of use and design the appropriate mechanisms to prevent employee exposures, property damage or release to the environment.

End Of Safety Data Sheet